- Home
- ECF vs PROK Comparison
ECF vs PROK Comparison
Compare ECF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECF
- PROK
- Stock Information
- Founded
- ECF 1986
- PROK 2015
- Country
- ECF United States
- PROK United States
- Employees
- ECF N/A
- PROK N/A
- Industry
- ECF Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECF Finance
- PROK Health Care
- Exchange
- ECF Nasdaq
- PROK Nasdaq
- Market Cap
- ECF 118.6M
- PROK 94.9M
- IPO Year
- ECF N/A
- PROK N/A
- Fundamental
- Price
- ECF $9.77
- PROK $0.81
- Analyst Decision
- ECF
- PROK Buy
- Analyst Count
- ECF 0
- PROK 4
- Target Price
- ECF N/A
- PROK $5.00
- AVG Volume (30 Days)
- ECF 57.7K
- PROK 796.9K
- Earning Date
- ECF 01-01-0001
- PROK 05-12-2025
- Dividend Yield
- ECF 6.42%
- PROK N/A
- EPS Growth
- ECF N/A
- PROK N/A
- EPS
- ECF 0.46
- PROK N/A
- Revenue
- ECF N/A
- PROK $306,000.00
- Revenue This Year
- ECF N/A
- PROK N/A
- Revenue Next Year
- ECF N/A
- PROK N/A
- P/E Ratio
- ECF $17.61
- PROK N/A
- Revenue Growth
- ECF N/A
- PROK N/A
- 52 Week Low
- ECF $7.02
- PROK $0.46
- 52 Week High
- ECF $8.91
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- ECF 70.94
- PROK 49.17
- Support Level
- ECF $9.69
- PROK $0.94
- Resistance Level
- ECF $9.34
- PROK $0.87
- Average True Range (ATR)
- ECF 0.15
- PROK 0.11
- MACD
- ECF 0.08
- PROK 0.01
- Stochastic Oscillator
- ECF 91.01
- PROK 39.10
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.